Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo

NCT07223229 is registered in ClinicalTrials.gov with Elixiron Immunotherapeutics (Hong Kong) Ltd. as lead sponsor.

NCT NCT07223229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo
Lead sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
December 30, 2025
Completion date
September 30, 2027
Enrollment
45 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-segmental vitiligo